OBJECTIVE: To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic markers and to relate these effects to changes in visceral adipose tissue (VAT). DESIGN AND METHODS: Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks. Circulating plasminogen activator inhibitor-1 (PAI-1) antigen, tissue plasminogen activator (tPA) antigen, C-reactive protein (CRP), and adiponectin were assessed. RESULTS: At baseline, VAT was significantly associated with PAI-1 antigen (ρ = 0.36, P < 0.001), tPA antigen (ρ = 0.29, P < 0.001), CRP (ρ = 0.18, P < 0.001), and adiponectin (ρ = -0.22, P < 0.001). Treatment with tesamorelin resulted in a significant decrease from baseline in tPA antigen (-2.2 ± 2.5 vs. -1.6 ± 2.9 ng/ml, tesamorelin vs. placebo, P < 0.05). Changes in PAI-1 antigen were not significant in the tesamorelin group compared to placebo. Among patients receiving tesamorelin, changes in inflammatory markers were associated with change in VAT (PAI-1 antigen: ρ = 0.16, P = 0.02; tPA antigen: ρ = 0.16, P = 0.02; adiponectin: ρ = -0.27, P < 0.001), and these associations remained significant when controlling for changes in insulin-like growth factor-1. CONCLUSION: In HIV patients with abdominal adiposity, tesamorelin may have a modest beneficial effect on adiponectin and fibrinolytic markers in association with changes in VAT. Further studies are needed to determine the clinical significance of these changes. These data further highlight the deleterious role of excessive VAT and the utility of strategies to improve VAT in this population.
RCT Entities:
OBJECTIVE: To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic markers and to relate these effects to changes in visceral adipose tissue (VAT). DESIGN AND METHODS: Four hundred and ten HIV-infectedpatients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks. Circulating plasminogen activator inhibitor-1 (PAI-1) antigen, tissue plasminogen activator (tPA) antigen, C-reactive protein (CRP), and adiponectin were assessed. RESULTS: At baseline, VAT was significantly associated with PAI-1 antigen (ρ = 0.36, P < 0.001), tPA antigen (ρ = 0.29, P < 0.001), CRP (ρ = 0.18, P < 0.001), and adiponectin (ρ = -0.22, P < 0.001). Treatment with tesamorelin resulted in a significant decrease from baseline in tPA antigen (-2.2 ± 2.5 vs. -1.6 ± 2.9 ng/ml, tesamorelin vs. placebo, P < 0.05). Changes in PAI-1 antigen were not significant in the tesamorelin group compared to placebo. Among patients receiving tesamorelin, changes in inflammatory markers were associated with change in VAT (PAI-1 antigen: ρ = 0.16, P = 0.02; tPA antigen: ρ = 0.16, P = 0.02; adiponectin: ρ = -0.27, P < 0.001), and these associations remained significant when controlling for changes in insulin-like growth factor-1. CONCLUSION: In HIVpatients with abdominal adiposity, tesamorelin may have a modest beneficial effect on adiponectin and fibrinolytic markers in association with changes in VAT. Further studies are needed to determine the clinical significance of these changes. These data further highlight the deleterious role of excessive VAT and the utility of strategies to improve VAT in this population.
Authors: Takara L Stanley; Cindy Y Chen; Karen L Branch; Hideo Makimura; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2010-10-13 Impact factor: 5.958
Authors: Susan A Phillips; Theodore P Ciaraldi; Alice P S Kong; Rahil Bandukwala; Vanita Aroda; Leslie Carter; Sunita Baxi; Sunder R Mudaliar; Robert R Henry Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Tobias Pischon; Cynthia J Girman; Gokhan S Hotamisligil; Nader Rifai; Frank B Hu; Eric B Rimm Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: G D O Lowe; J Danesh; S Lewington; M Walker; L Lennon; A Thomson; A Rumley; P H Whincup Journal: Eur Heart J Date: 2004-02 Impact factor: 29.983
Authors: Alice S Ryan; Dora M Berman; Barbara J Nicklas; Madhur Sinha; Ronald L Gingerich; Grady S Meneilly; Josephine M Egan; Dariush Elahi Journal: Diabetes Care Date: 2003-08 Impact factor: 19.112
Authors: Vivien Leung; Ya-Lin Chiu; Donald P Kotler; Jeanine Albu; Yuan-Shan Zhu; Kirsis Ham; Ellen S Engelson; Hoda Hammad; Paul Christos; Daniel S Donovan; Henry N Ginsberg; Marshall J Glesby Journal: HIV Clin Trials Date: 2016-02-01